Replies to post #3984 on BioCurex, Inc.(fka BOCX)

[erthang]

"These results complement those previously announced for breast cancer and they strongly suggest that the RECAF blood test could detect early stages of all the major cancer types"

I think Dr. Moro believes based on lab research and results, that recaf can detect early stages of all of the major cancer types. He prefaced that with words like "could" and "strongly suggest", which reminds me of a disclosure statement, probably until it can be validated by outside labs. The company already got in trouble for statements that weren't symantically correct, he is just being careful. I don't think he would have even made the statement, unless he felt very positively about the results of their research, "STRONGLY suggest that the RECAF blood test could detect early stages of all the major cancer types". This clearly is very positive news for investors.

Kag - any attempts to read something negatively into the last pr is ridiculous, as I'm sure most on this board will agree! So save it, man!

[Headache]

Rather than continuing to fret about Kag's hermeneutical treatment of the latest PRs, I decided to ask Dr. Moro whether the statement that "We do not know yet if the normal RECAF concentration is constant enough to make this personalization possible" from the May 16 release has any bearing on the standard assay. He basically said it does not, reiterating the natural interpretation (at least for me) of the PR that he was discussing a possible improvement of the test when he made the remarks about personalization. Nothing in the PR should be construed as casting the RECAF enterprise into doubt. If you really need him to reiterate the contents of the PR for you you, by all means contact him. But I suggest we just let him get back to fighting the good fight.

END OF STORY. Let's move on now.